سوق علاج الورم الأرومي الدبقي متعدد الأشكال في منطقة آسيا والمحيط الهادئ - اتجاهات الصناعة والتوقعات حتى عام 2029

Request for TOC طلب جدول المحتويات Speak to Analyst تحدث إلى المحلل Buy Now اشتري الآن Inquire Before Buying استفسر قبل Free Sample Report تقرير عينة مجاني

سوق علاج الورم الأرومي الدبقي متعدد الأشكال في منطقة آسيا والمحيط الهادئ - اتجاهات الصناعة والتوقعات حتى عام 2029

  • Pharmaceutical
  • Published Report
  • May 2022
  • Asia-Pacific
  • 350 الصفحات
  • عدد الجداول: 258
  • عدد الأرقام: 49

>سوق علاج الورم الأرومي الدبقي متعدد الأشكال في منطقة آسيا والمحيط الهادئ، حسب النوع (أولي (جديد)، ثانوي)، العلاج (الجراحة، العلاج الإشعاعي ، الأدوية)، نوع المريض (بالغ، مسن ، طفل)، نوع الدواء (الأدوية الجنيسة، ذات العلامة التجارية)، طريق الإدارة (الحقن، الفموي، أخرى)، المستخدم النهائي (المستشفيات، العيادات، الرعاية الصحية المنزلية، أخرى)، قناة التوزيع (صيدلية المستشفى، صيدلية التجزئة، صيدلية الإنترنت، أخرى) اتجاهات الصناعة والتوقعات حتى عام 2029.

سوق علاج الورم الأرومي الدبقي متعدد الأشكال في منطقة آسيا والمحيط الهادئ

تحليل السوق والرؤى

الورم الأرومي الدبقي متعدد الأشكال (GBM) هو ورم خبيث من الدرجة الرابعة وفقًا لمنظمة الصحة العالمية مع تمايز نجمي. باعتباره أحد أكثر مداخل الأورام شيوعًا التي يتم تشخيصها سريريًا في الجهاز العصبي المركزي (CNS)، كانت هناك مجموعة واسعة من التقارير التاريخية لوصف وتطور الأفكار المتعلقة بهذه الأورام. تم تقديم التقارير المسجلة الأولى للأورام الدبقية في التقارير العلمية البريطانية، بواسطة بيرنز في عام 1800 وفي عام 1804 بواسطة أبيرنيتي، مع إعطاء أول وصف هيستومورفولوجي شامل في عام 1865 بواسطة رودولف فيرشو. في عام 1926، أعطى بيرسيفال بيلي وهارفي كوشينج الأساس للتصنيف الحديث للأورام الدبقية. بين عامي 1934 و1941 كان الباحث الأكثر غزارة في أبحاث الأورام الدبقية هو هانز يواكيم شيرر، الذي افترض بعض الجوانب السريرية والمورفولوجية للورم الأرومي الدبقي متعدد الأشكال. مع إدخال الاختبارات الجزيئية والوراثية، تم تحديد التعدد الحقيقي لأورام الدماغ متعددة الأشكال، حيث تحمل الأنماط الجينية المختلفة نفس الصورة الهيستومورفولوجية وIHC، بالإضافة إلى بعض جوانب تكوين الورم الدبقي. لكي يتطور الورم الدماغي متعدد الأشكال، يجب أن تحدث طفرة محفزة محددة في الخلية الجذعية للورم الدماغي متعدد الأشكال - الورم الدماغي متعدد الأشكال الأولي، أو التجمع البطيء للطفرات الفردية، دون طفرة محفزة مميزة - الورم الدماغي متعدد الأشكال الثانوي. كانت معرفة الورم الدماغي متعدد الأشكال مرتبطة ارتباطًا وثيقًا بالمعرفة الطبية العامة للجهاز العصبي المركزي منذ وصف هذه الأورام الخبيثة لأول مرة منذ أكثر من 200 عام. تم تحقيق عدة قفزات كبيرة في ذلك الوقت، على خطى الجهاز العصبي المركزي والتقدم في المعرفة الطبية العامة. يتزايد الطلب على علاج الورم الدماغي متعدد الأشكال، والذي تشارك الشركات المصنعة في إطلاق المنتجات الجديدة له، وزيادة منتجات خطوط الأنابيب والمشاركة في الأحداث في السوق. تعمل هذه القرارات في نهاية المطاف على تعزيز نمو السوق. 

سوق علاج الورم الأرومي الدبقي متعدد الأشكال

سوق علاج الورم الأرومي الدبقي متعدد الأشكال

The glioblastoma multiforme treatment market report provides details of market share, new developments, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. Strategic initiatives such as collaboration, agreement, and signing  of sales agreements to invent and innovate pharmacological treatments are the major drivers which propelled the demand of the market in the forecast period.

The glioblastoma multiforme treatment market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that  glioblastoma multiforme treatment market will grow at a CAGR of 9.2% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Type (Primary (De Novo), Secondary),  Treatment (Surgery, Radiotherapy, Medications),  Patient Type (Adult, Geriatric, Child), Drug Type (Generics, Branded), Route of Administration (Parenteral, Oral, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.

Market Players Covered

F. Hoffmann-La Roche AG, Amgen Inc., Merck & Co., Inc., Pfizer Inc., Varian Medical Systems, Inc.  (A subsidiary of Siemens Healthcare), ZEISS International, Amneal Pharmaceuticals LLC, Elekta, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Eckert & Ziegler, Accord Healthcare, Angiochem, ANI Pharmaceuticals, Inc., Arbor Pharmaceuticals, LLC.  (A Subsidiary of Azurity Pharmaceuticals, Inc.), AstraZeneca, Cantex Pharmaceuticals, Inc., CELON LABS, Diffusion Pharmaceuticals Inc., EnGeneIC, ERC.SA., Genenta science, Jazz Pharmaceuticals, Inc., Loxo Oncology (A Subsidiary of Eli Lilly), Novartis AG, VBL THERAPEUTICS, Viatris Inc., and Zydus Pharmaceuticals, Inc., among others.

MARKET DEFINITION

Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor and accounts for 60% of brain tumors in adults. GBMs can arise in the brain de novo or evolve from lower-grade astrocytoma. In adults, GBM occurs most often in the cerebral hemispheres, especially in the frontal and temporal lobes of the brain. Many genetic and environmental factors have been studied in glioblastoma multiforme, but no risk factor that accounts for a large proportion of GBM has been identified. So like many other cancers, GBM is sporadic, although some studies indicate a high prevalence (17%) of prior therapeutic irradiation among patients with GBM. The latency between irradiation and the development of GBM varies from a few years to several decades. There is no substantial evidence of GBM association with lifestyle factors like smoking, alcohol consumption, drug use, or exposure to N- Nitroso compounds. Studies have shown that the use of mobile phones doesn't increase the risk of development of GBM; however, its association with long term use needs further confirmation.                               

Glioblastoma Multiforme Treatment Market Dynamics

Drivers

  • Growing prevalence of glioblastoma multiforme

Glioblastoma multiforme (GBM) is the most commonly occurring malignant primary brain tumor, representing 77%-81% of all central nervous system (CNS) primary malignant tumors. The World Health Organization classified it as a grade IV diffuse astrocytic and oligodendroglial tumor. The mean age of primary GBM presentation is 62 years, and the median survival is approximately 14.6 months. The poor prognosis associated with GBM is well documented, while survival rates remain disappointingly low despite medical and surgical advances. As per the study, International studies reveal an approximate annual incidence rate of 0.59 to 5 per 100,000 persons; however, studies indicate a rise in incidence. Miranda-Filho et al. in 2017 described increasing rates of CNS and brain cancers in countries in South America, Eastern Europe, and Southern Europe, while decreasing rates were only reported in Japan. Dobes et al. in 2011 have also noted an increasing incidence of GBM tumors in two of their multicentered Australian studies, with a particular increase in frontal and temporal lobe GBM tumors. The increased incidence of glioblastoma multiforme raises the demand for early detection and diagnosis via utilizing the latest technology, propelling the global glioblastoma multiforme treatment market. The rising incidence of glioblastoma across the globe is expected to accelerate the demand for glioblastoma multiforme treatment. Thus, the increased incidence rates of glioblastoma multiforme are expected to boost the market's growth.

  • Increasing research and development (r&d)

Increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side effects of the existing treatment methods, thus creating broader acceptance amongst patients. Tumor heterogeneity and variation in the patient-to-patient treatment approach are expected to increase the demand for a personalized treatment approach to manage glioblastoma  multiforme. The approval of new treatments is expected to increase the life expectancy of patients living with glioblastoma multiforme. Furthermore, a special designation granted to investigational drugs by the FDA is expected to expedite novel therapy's approval process and commercialization. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme. The increasing approval for novel therapy and combination therapy is expected to drive theglioblastoma multiforme treatment market. 

Opportunity

  • Increasing drug approvals

The escalating demand for glioblastoma multiforme treatment should yield more regulatory approvals for associated drugs. Increasing regulatory endorsements for related drugs and recombinant products will constitute an increase in glioblastoma multiforme treatment market value in the coming years. In the framework of a Pan American Health Organization (PAHO) initiative to promote the recognition of Drug Regulatory Authorities, ANMAT´s evaluation process finished on December 11, 2009. The glioblastoma multiforme treatment industry has witnessed numerous drug approvals in recent years, driven by the increasing fatality rate of the disease. Increasing drug approvals will ramp up the glioblastoma multiforme treatment market demand.

Restraints/Challenges

High cost of glioblastoma multiforme treatment

The diagnostic tests for glioblastoma multiforme include highly technologically advanced products. Developing those products involves rigorous research and development by the developing player. Thus, the cost of the product remains high, which proportionally increases the cost of testing.

The diagnostic tools and techniques used for the diagnosis of glioblastoma multiforme include

radiation therapy, chemotherapy, among others. Early stages of GBM typically present with minimal or no symptoms; therefore, GBM is frequently diagnosed at advanced stages, resulting in a poor prognosis. Thus, the high cost of treating the glioblastoma multiforme using the advanced modalities and technology products will act as a major restraining factor for the growth of the global glioblastoma multiforme treatment market.

Recent Developments

  • في أبريل 2022، أعلنت شركة إليكتا وجنرال إلكتريك للرعاية الصحية عن توقيع اتفاقية تعاون تجاري عالمي في مجال علاج الأورام بالإشعاع، مما يمكنهم من تقديم عرض شامل للمستشفيات عبر التصوير والعلاج لمرضى السرطان الذين يحتاجون إلى العلاج الإشعاعي. ستسمح هذه الشراكة للشركتين بالترويج المشترك للحلول لتلبية احتياجات كل مركز للسرطان
  • في يوليو 2019، أعلنت شركة أمجين وشركة أليرجان أن عقار MVASI (bevacizumab-awwb)، وهو عقار مشابه حيويًا لعقار أفاستين (bevacizumab)، متاح في الولايات المتحدة. ومن شأن هذا الإطلاق أن يعزز مبيعات المنتج في المنطقة

نطاق سوق علاج الورم الأرومي الدبقي متعدد الأشكال

يتم تصنيف سوق علاج الورم الأرومي الدبقي متعدد الأشكال إلى سبعة قطاعات بارزة تعتمد على النوع والعلاج ونوع المريض ونوع الدواء وطريقة الإدارة والمستخدم النهائي وقناة التوزيع. يساعدك النمو بين القطاعات على تحليل جيوب النمو والاستراتيجيات المتخصصة للتعامل مع السوق وتحديد مجالات التطبيق الأساسية والاختلاف في الأسواق المستهدفة.

يكتب

  • الابتدائية (دي نوفو)
  • ثانوي

على أساس النوع، يتم تقسيم سوق علاج الورم الأرومي الدبقي متعدد الأشكال إلى أولي (De Novo) وثانوي.

علاج

على أساس العلاج، يتم تقسيم سوق علاج الورم الأرومي الدبقي متعدد الأشكال إلى الجراحة والعلاج الإشعاعي والأدوية.

نوع المريض

  • بالغ
  • كبار السن
  • طفل

على أساس نوع المريض، يتم تقسيم سوق علاج الورم الأرومي الدبقي متعدد الأشكال إلى البالغين وكبار السن والأطفال.

نوع الدواء

  • العلامة التجارية
  • الأنواع العامة

على أساس نوع الدواء، يتم تقسيم سوق علاج الورم الأرومي الدبقي متعدد الأشكال إلى أدوية عامة وأدوية ذات علامات تجارية.

طريق الإدارة

  • شفوي
  • الحقن الوريدي
  • آحرون

على أساس طريق الإدارة، يتم تقسيم سوق علاج الورم الأرومي الدبقي متعدد الأشكال إلى علاج بالحقن والفم وغيرها.

المستخدم النهائي

  • المستشفيات
  • العيادات
  • الرعاية الصحية المنزلية
  • آحرون

على أساس المستخدم النهائي، يتم تقسيم سوق علاج الورم الأرومي الدبقي متعدد الأشكال إلى المستشفيات والعيادات والرعاية الصحية المنزلية وغيرها.

قناة التوزيع

  • صيدلية المستشفى
  • صيدلية التجزئة
  • صيدلية على الإنترنت
  • آحرون

سوق علاج الورم الأرومي الدبقي متعدد الأشكال

على أساس قناة التوزيع، يتم تقسيم سوق علاج الورم الأرومي الدبقي متعدد الأشكال إلى صيدلية المستشفيات وصيدلية التجزئة وغيرها.

تحليل إقليمي/رؤى حول سوق علاج الورم الأرومي الدبقي متعدد الأشكال

يتم تحليل سوق علاج الورم الأرومي الدبقي متعدد الأشكال ويتم توفير رؤى حجم السوق والاتجاهات حسب النوع والعلاج ونوع المريض ونوع الدواء وطريقة الإدارة والمستخدم النهائي وقناة التوزيع كما هو مذكور أعلاه.

المناطق التي يغطيها تقرير سوق علاج الورم الأرومي الدبقي متعدد الأشكال هي الصين واليابان والهند وكوريا الجنوبية وسنغافورة وماليزيا وأستراليا وتايلاند وإندونيسيا والفلبين وفيتنام وبقية دول آسيا والمحيط الهادئ.

ومن المتوقع أن تهيمن اليابان على سوق منطقة آسيا والمحيط الهادئ بسبب زيادة أنشطة البحث والتطوير في البلاد.

كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغيرات في تنظيم السوق التي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. نقاط البيانات مثل تحليل سلسلة القيمة المصب والمصب، والاتجاهات الفنية وتحليل قوى بورتر الخمس، ودراسات الحالة هي بعض المؤشرات المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية العالمية والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية، وتأثير التعريفات الجمركية المحلية وطرق التجارة أثناء تقديم تحليل توقعات لبيانات الدولة.   

تحليل المنافسة وحصة سوق علاج الورم الأرومي الدبقي متعدد الأشكال

يوفر المشهد التنافسي لسوق علاج الورم الأرومي الدبقي متعدد الأشكال تفاصيل عن المنافسين. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور العالمي، ومواقع الإنتاج والمرافق، والقدرات الإنتاجية، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات على سوق علاج الورم الأرومي الدبقي متعدد الأشكال.

بعض اللاعبين الرئيسيين في السوق هم F. Hoffmann-La Roche AG، Amgen Inc.، Merck & Co.، Inc.، Pfizer Inc.، Varian Medical Systems، Inc. (شركة تابعة لشركة Siemens Healthcare)، ZEISS International، Amneal Pharmaceuticals LLC، Elekta، Sun Pharmaceutical Industries Ltd، Teva Pharmaceutical Industries Ltd.، Eckert & Ziegler، Accord Healthcare، Angiochem، ANI Pharmaceuticals، Inc.، Arbor Pharmaceuticals، LLC. (شركة تابعة لشركة Azurity Pharmaceuticals, Inc.)، وAstraZeneca، وCantex Pharmaceuticals, Inc.، وCELON LABS، وDiffusion Pharmaceuticals Inc.، وEnGeneIC، وERC.SA.، وGenenta science، وJazz Pharmaceuticals, Inc.، وLoxo Oncology (شركة تابعة لشركة Eli Lilly)، وNovartis AG، وVBL THERAPEUTICS، وViatris Inc.، وZydus Pharmaceuticals, Inc.، وغيرها.

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. بالإضافة إلى ذلك، يعد تحليل حصة السوق وتحليل الاتجاهات الرئيسية من عوامل النجاح الرئيسية في تقرير السوق. منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تنطوي على استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأساسي (خبير الصناعة). وبصرف النظر عن هذا، تتضمن نماذج البيانات شبكة وضع البائعين وتحليل الخط الزمني للسوق ونظرة عامة على السوق والدليل وشبكة وضع الشركة وتحليل حصة الشركة في السوق ومعايير القياس والتحليل العالمي مقابل الإقليمي وتحليل حصة البائعين. يرجى طلب مكالمة محلل في حالة وجود استفسار آخر.


SKU-

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

  • لوحة معلومات تحليل البيانات التفاعلية
  • لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
  • إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
  • تحليل المنافسين باستخدام لوحة معلومات تفاعلية
  • آخر الأخبار والتحديثات وتحليل الاتجاهات
  • استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS

7 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: REGULATORY SCENARIO

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 GROWING PREVALENCE OF GLIOBLASTOMA MULTIFORME

8.1.2 INCREASING RESEARCH AND DEVELOPMENT (R&D)

8.1.3 PRESENCE OF A STRONG PIPELINE

8.1.4 GROWING GERIATRIC POPULATION

8.2 RESTRAINTS

8.2.1 HIGH COST OF GLIOBLASTOMA MULTIFORME TREATMENT

8.2.2 ADVERSE SIDE-EFFECTS OF GLIOBLASTOMA MULTIFORME TREATMENT

8.3 OPPORTUNITIES

8.3.1 INCREASING DRUG APPROVALS

8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS

8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT

8.4 CHALLENGES

8.4.1 LACK OF NEW TREATMENT

8.4.2 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS

8.4.3 LACK OF EARLY DETECTION

9 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE

9.1 OVERVIEW

9.2 PRIMARY (DE NOVO)

9.3 SECONDARY

10 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 SURGERY

10.3 RADIOTHERAPY

10.3.1 BRACHYTHERAPY

10.3.2 FRACTIONATED STEREOTACTIC RT (FSRT)

10.3.3 CONFORMAL OR INTENSITY-MODULATED RT

10.3.4 RADIOSURGERY

10.4 MEDICATIONS

10.4.1 TEMOZOLOMIDE

10.4.1.1 ORAL

10.4.1.1 INTRAVENOUS

10.4.2 NITROSOUREAS DRUGS

10.4.2.1 CARMUSTINE

10.4.2.1.1 PARENTERAL

10.4.2.1.2 IMPLANTABLE WAFERS

10.4.2.2 LOMUSTINE

10.4.2.3 NIMUSTINE

10.4.2.4 FOTEMUSTINE

10.4.3 TARGETED THERAPY

10.4.3.1 BEVACIZUMAB

10.4.3.2 OTHERS

10.4.4 ANTI-EPILEPTICS

10.4.4.1 LEVETIRACETAM

10.4.4.2 PHENYTOIN

10.4.4.3 CARBAMAZEPINE

10.4.5 CORTICOSTEROIDS

10.4.5.1 METHYLPREDNISOLONE

10.4.5.2 PREDNISONE

10.4.5.3 OTHERS

11 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE

11.1 OVERVIEW

11.2 ADULT

11.2.1 MALE

11.2.2 FEMALE

11.3 GERIATRIC

11.3.1 MALE

11.3.2 FEMALE

11.4 CHILD

12 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 GENERICS

12.3 BRANDED

13 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 PARENTERAL

13.3 ORAL

13.3.1 CAPSULES

13.3.2 TABLETS

13.3.3 POWDERS

13.4 OTHERS

14 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITAL

14.3 CLINICS

14.4 HOME HEALTHCARE

14.5 OTHERS

15 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 HOSPITAL PHARMACY

15.3 RETAIL PHARMACY

15.4 ONLINE PHARMACY

15.5 OTHERS

16 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION

16.1 ASIA-PACIFIC

16.1.1 JAPAN

16.1.2 CHINA

16.1.3 INDIA

16.1.4 AUSTRALIA

16.1.5 SOUTH KOREA

16.1.6 SINGAPORE

16.1.7 THAILAND

16.1.8 INDONESIA

16.1.9 PHILIPPINES

16.1.10 MALAYSIA

16.1.11 VIETNAM

16.1.12 REST OF ASIA-PACIFIC

17 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 F.HOFFMAN-LA ROCHE

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 AMGEN INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.2.5.1 PRODUCT APPROVAL

19.3 MERCK & CO., INC

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.3.5.1 STRATETIC COLLABORATION

19.3.5.2 EVENTS

19.4 PFIZER INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.4.5.1 MERGER

19.5 VARIAN MEDICAL SYSTEMS, INC. (A SUBSIDIARY OF SIEMENS HEALTHCARE)

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.5.5.1 PARTNERSHIP

19.5.5.2 ACQUISITION

19.6 ZEISS INTERNATIONAL

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENTS

19.6.4.1 PRODUCT EXPANSION

19.7 AMNEAL PHARMACEUTICALS LLC

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.7.4.1 EVENT

19.7.4.2 LAUNCH

19.7.4.3 ACQUISITION

19.8 ELEKTA

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.8.4.1 PARTNERSHIP

19.9 SUN PHARMACEUTICAL INDUSTRIES LTD

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.9.4.1 AGREEMENT

19.1 TEVA PHARMACEUTICAL INDUSTRIES LTD

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 ECKERT & ZIEGLER

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 ACCORD HEALTHCARE

19.12.1 COMPANY SNAPSHOT

19.12.2 PRODUCT PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 ANGIOCHEM

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.13.3.1 AGREMEENT

19.14 ANI PHARMACEUTICALS, INC.

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.14.4.1 ACQUISITION

19.15 ARBOR PHARMACEUTICALS, LLC. A SUBSIDIARY OF AZURITY PHARMACEUTICALS, INC.

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.15.3.1 ACQUISITION

19.15.3.2 PRODUCT APPROVAL

19.16 ASTRAZENECA

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.16.4.1 AGREEMENT

19.17 CANTEX PHARMACEUTICALS, INC.

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENT

19.18 CELON LABS

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENT

19.19 DIFFUSION PHARMACEUTICAL

19.19.1 COMPANY SNAPSHOT

19.19.2 SERVICES PORTFOLIO

19.19.3 RECENT DEVELOPMENT

19.2 ERC.SA

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENT

19.20.3.1 PIPELINE UPDATE

19.21 ENGENEIC

19.21.1 COMPANY SNAPSHOT

19.21.2 PRODUCT PORTFOLIO

19.21.3 RECENT DEVELOPMENTS

19.21.3.1 AWARDS

19.22 GENENTA SCIENCE

19.22.1 COMPANY SNAPSHOT

19.22.2 PRODUCT PORTFOLIO

19.22.3 RECENT DEVELOPMENT

19.22.3.1 EVENT

19.23 JAZZ PHARMACEUTICALS, INC.

19.23.1 COMPANY SNAPSHOT

19.23.2 REVENUE ANALYSIS

19.23.3 PRODUCT PORTFOLIO

19.23.4 RECENT DEVELOPMENT

19.23.4.1 ACQUISITION

19.24 LOXO ONCOLOGY (A SUBSIDIARY OF ELI LILLY)

19.24.1 COMPANY SNAPSHOT

19.24.2 PRODUCT PORTFOLIO

19.24.3 RECENT DEVELOPMENT

19.25 NOVARTIS AG

19.25.1 COMPANY SNAPSHOT

19.25.2 REVENUE ANALYSIS

19.25.3 PRODUCT PORTFOLIO

19.25.4 RECENT DEVELOPMENT

19.26 VBL THERAPEUTICS

19.26.1 COMPANY SNAPSHOT

19.26.2 PRODUCT PORTFOLIO

19.26.3 RECENT DEVELOPMENT

19.26.3.1 EVENT

19.26.3.2 AWARD

19.27 VIATRIS INC

19.27.1 COMPANY SNAPSHOT

19.27.2 REVENUE ANALYSIS

19.27.3 PRODUCT PORTFOLIO

19.27.4 RECENT DEVELOPMENT

19.27.4.1 AGREEMENT

19.28 ZYDUS PHARMACEUTICALS, INC.

19.28.1 COMPANY SNAPSHOT

19.28.2 PRODUCT PORTFOLIO

19.28.3 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

List of Table

TABLE 1 PIPELINE ANALYSIS FOR GLIOBLASTOMA MULTIFORME TREATMENT MARKET

TABLE 2 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC PRIMARY (DE NOVO) IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC SECONDARY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC SURGERY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC ADULTS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC CHILD IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC GENERICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC BRANDED IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC PARENTERAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 30 ASIA PACIFIC OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 ASIA PACIFIC HOSPITAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 ASIA PACIFIC CLINICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 ASIA PACIFIC HOME HEALTHCARE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 ASIA PACIFIC OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 37 ASIA PACIFIC HOSPITAL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 ASIA PACIFIC RETAIL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 ASIA PACIFIC ONLINE PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 ASIA PACIFIC OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 42 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 44 ASIA-PACIFIC RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 45 ASIA-PACIFIC MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 46 ASIA-PACIFIC TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 ASIA-PACIFIC NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 48 ASIA-PACIFIC CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 49 ASIA-PACIFIC TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 50 ASIA-PACIFIC ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 ASIA-PACIFIC CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 53 ASIA-PACIFIC ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 54 ASIA-PACIFIC GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 55 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 56 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 57 ASIA-PACIFIC ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 58 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 59 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 60 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 62 JAPAN RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 63 JAPAN MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 64 JAPAN TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 65 JAPAN NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 66 JAPAN CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 67 JAPAN TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 68 JAPAN ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 69 JAPAN CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 70 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 71 JAPAN ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 72 JAPAN GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 73 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 74 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 75 JAPAN ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 76 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 77 JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 78 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 CHINA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 CHINA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 CHINA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 CHINA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 84 CHINA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 85 CHINA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 86 CHINA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 87 CHINA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 88 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 89 CHINA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 90 CHINA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 91 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 92 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 93 CHINA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 94 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 95 CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 96 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 98 INDIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 99 INDIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 100 INDIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 101 INDIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 102 INDIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 103 INDIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 104 INDIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 105 INDIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 106 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 107 INDIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 108 INDIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 109 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 110 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 111 INDIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 112 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 113 INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 114 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 115 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 116 AUSTRALIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 117 AUSTRALIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 118 AUSTRALIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 119 AUSTRALIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 120 AUSTRALIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 121 AUSTRALIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 122 AUSTRALIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 123 AUSTRALIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 124 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 125 AUSTRALIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 126 AUSTRALIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 127 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 128 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 129 AUSTRALIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 130 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 131 AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 132 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 133 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 134 SOUTH KOREA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 135 SOUTH KOREA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 136 SOUTH KOREA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 137 SOUTH KOREA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 138 SOUTH KOREA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 139 SOUTH KOREA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 140 SOUTH KOREA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 141 SOUTH KOREA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 142 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 143 SOUTH KOREA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 144 SOUTH KOREA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 145 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 146 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 147 SOUTH KOREA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 148 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 149 SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 150 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 151 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 152 SINGAPORE RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 153 SINGAPORE MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 154 SINGAPORE TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 155 SINGAPORE NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 156 SINGAPORE CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 157 SINGAPORE TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 158 SINGAPORE ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 159 SINGAPORE CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 160 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 161 SINGAPORE ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 162 SINGAPORE GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 163 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 164 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 165 SINGAPORE ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 166 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 167 SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 168 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 169 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 170 THAILAND RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 171 THAILAND MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 172 THAILAND TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 173 THAILAND NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 174 THAILAND CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 175 THAILAND TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 176 THAILAND ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 177 THAILAND CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 178 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 179 THAILAND ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 180 THAILAND GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 181 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 182 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 183 THAILAND ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 184 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 185 THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 186 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 187 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 188 INDONESIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 189 INDONESIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 190 INDONESIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 191 INDONESIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 192 INDONESIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 193 INDONESIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 194 INDONESIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 195 INDONESIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 196 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 197 INDONESIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 198 INDONESIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 199 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 200 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 201 INDONESIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 202 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 203 INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 204 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 205 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 206 PHILIPPINES RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 207 PHILIPPINES MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 208 PHILIPPINES TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 209 PHILIPPINES NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 210 PHILIPPINES CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 211 PHILIPPINES TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 212 PHILIPPINES ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 213 PHILIPPINES CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 214 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 215 PHILIPPINES ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 216 PHILIPPINES GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 217 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 218 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 219 PHILIPPINES ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 220 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 221 PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 222 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 223 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 224 MALAYSIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 225 MALAYSIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 226 MALAYSIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 227 MALAYSIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 228 MALAYSIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 229 MALAYSIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 230 MALAYSIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 231 MALAYSIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 232 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 233 MALAYSIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 234 MALAYSIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 235 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 236 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 237 MALAYSIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 238 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 239 MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 240 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 241 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 242 VIETNAM RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 243 VIETNAM MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 244 VIETNAM TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 245 VIETNAM NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 246 VIETNAM CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 247 VIETNAM TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 248 VIETNAM ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 249 VIETNAM CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 250 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 251 VIETNAM ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 252 VIETNAM GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 253 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 254 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 255 VIETNAM ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 256 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 257 VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 258 REST OF ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 INCREASE IN THE PREVALENCE OF GLIOBLASTOMA MULTIFORME AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 PRIMARY (DE NOVO) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN 2022 & 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET

FIGURE 16 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2021

FIGURE 17 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 18 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2021

FIGURE 21 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2022-2029 (USD MILLION)

FIGURE 22 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, CAGR (2022-2029)

FIGURE 23 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, LIFELINE CURVE

FIGURE 24 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2021

FIGURE 25 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)

FIGURE 26 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 27 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 28 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2021

FIGURE 29 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)

FIGURE 30 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029)

FIGURE 31 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 32 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 33 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 34 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 35 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2021

FIGURE 37 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 38 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 39 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 41 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 42 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 43 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 45 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022)

FIGURE 46 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 47 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 48 ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022 & 2029)

FIGURE 49 ASIA PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

The Asia-Pacific Glioblastoma Multiforme Treatment Market will grow at a CAGR of 9.2% during the forecast by 2029.
The significant factors flourishing the growth of the Asia-Pacific Glioblastoma Multiforme Treatment Market are Growing prevalence of glioblastoma multiforme, and Increasing research and development (r&d).
The major players operating in the Asia-Pacific Glioblastoma Multiforme Treatment Market are F. Hoffmann-La Roche AG, Amgen Inc., Merck & Co., Inc., Pfizer Inc., Varian Medical Systems, Inc. (A subsidiary of Siemens Healthcare), ZEISS International, Amneal Pharmaceuticals LLC, Elekta, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Eckert & Ziegler, Accord Healthcare, Angiochem, ANI Pharmaceuticals, Inc., Arbor Pharmaceuticals, LLC. (A Subsidiary of Azurity Pharmaceuticals, Inc.), AstraZeneca, Cantex Pharmaceuticals, Inc., CELON LABS, Diffusion Pharmaceuticals Inc., EnGeneIC, ERC.SA., Genenta science, Jazz Pharmaceuticals, Inc., Loxo Oncology (A Subsidiary of Eli Lilly), Novartis AG, VBL THERAPEUTICS, Viatris Inc., and Zydus Pharmaceuticals, Inc., among others.
The major countries covered in the Asia-Pacific Glioblastoma Multiforme Treatment Market are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.